Terjemahan ini masih disiapkan. Sementara itu, kami menampilkan versi asli bahasa Inggris.
Startup · 27/10/20261 min read
Orphan Therapeutics Accelerator In-Licenses Investigational Gene Therapy Program for Ornithine Transcarbamylase Deficiency from UCL Ventures and Children's Medical Research Institute
Terjemahan otomatis lokal · Bahasa asli sumber
Ringkasan
OTXL-101, a promising therapy in development for a severe, rare pediatric metabolic condition, becomes the first pipeline program to be in-licensed by Orphan Therapeutics Accelerator (OTXL) CAMBRIDGE, Mass., Oct. 27,…
Bahasa asli sumber: PR Newswire UK — News ReleasesBaca sumber asli →